Spero Therapeutics (SPRO) Cash & Current Investments (2016 - 2026)
Quarterly Cash & Current Investments rose 14.81% to $56.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56.1 million through Mar 2026, up 14.81% year-over-year, with the annual reading at $40.3 million for FY2025, 23.87% down from the prior year.
Spero Therapeutics filings provide 11 years of Cash & Current Investments readings, the most recent being $56.1 million for Q1 2026.
- Cash & Current Investments hit $56.1 million in Q1 2026 for Spero Therapeutics, up from $40.3 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $122.0 million in Q1 2022 and bottomed at $31.2 million in Q2 2025.
- Average Cash & Current Investments over 5 years is $68.9 million, with a median of $63.5 million recorded in 2024.
- The largest annual shift saw Cash & Current Investments crashed 59.13% in 2022 before it surged 85.99% in 2023.
- Spero Therapeutics' Cash & Current Investments stood at $109.1 million in 2022, then tumbled by 30.04% to $76.3 million in 2023, then plummeted by 30.71% to $52.9 million in 2024, then fell by 23.87% to $40.3 million in 2025, then soared by 39.4% to $56.1 million in 2026.
- Per Business Quant, the three most recent readings for SPRO's Cash & Current Investments are $56.1 million (Q1 2026), $40.3 million (Q4 2025), and $48.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 901.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 8.75 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 18.44 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Spero Therapeutics | 154.37 Mn | 98.24 Mn | - | 56.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.13 Mn |
| Dec 31, 2025 | 40.27 Mn |
| Sep 30, 2025 | 48.62 Mn |
| Jun 30, 2025 | 31.19 Mn |
| Mar 31, 2025 | 48.89 Mn |
| Dec 31, 2024 | 52.89 Mn |
| Sep 30, 2024 | 76.29 Mn |
| Jun 30, 2024 | 63.53 Mn |
| Mar 31, 2024 | 82.27 Mn |
| Dec 31, 2023 | 76.33 Mn |
| Sep 30, 2023 | 93.83 Mn |
| Jun 30, 2023 | 77.69 Mn |
| Mar 31, 2023 | 96.25 Mn |
| Dec 31, 2022 | 109.11 Mn |
| Sep 30, 2022 | 50.45 Mn |
| Jun 30, 2022 | 45.40 Mn |
| Mar 31, 2022 | 121.97 Mn |
| Dec 31, 2021 | 146.40 Mn |
| Sep 30, 2021 | 123.42 Mn |
| Jun 30, 2021 | 99.22 Mn |
| Mar 31, 2021 | 115.68 Mn |
| Dec 31, 2020 | 126.91 Mn |
| Sep 30, 2020 | 127.24 Mn |
| Jun 30, 2020 | 71.36 Mn |
| Mar 31, 2020 | 88.84 Mn |
| Dec 31, 2019 | 82.05 Mn |
| Sep 30, 2019 | 93.86 Mn |
| Jun 30, 2019 | 103.41 Mn |
| Mar 31, 2019 | 106.39 Mn |
| Dec 31, 2018 | 115.44 Mn |
| Sep 30, 2018 | 131.23 Mn |
| Jun 30, 2018 | 66.64 Mn |
| Mar 31, 2018 | 75.39 Mn |
| Dec 31, 2017 | 87.29 Mn |
| Sep 30, 2017 | 25.37 Mn |
| Dec 31, 2016 | 10.32 Mn |
| Sep 30, 2016 | 11.28 Mn |